Novo Nordisk has blamed middlemen in the U.S. healthcare system for the high prices of its top-selling weight-loss drugs Wegovy and Ozempic, following the launch of an investigation into the drugs ...

CVS Caremark, which forms the eponymous pharmacy chain’s drug benefits unit, is the largest pharmacy benefit manager in the U.S., as Novo pointed out. The move will knock Lilly’s dual GIP/GLP ...

CagriSema combines the GLP-1 agonist semaglutide in Novo Nordisk's blockbuster weight-loss drug Wegovy with dual amylin and calcitonin receptor agonist cagrilintide. The company is hoping that the ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic diseases, as it pays $200 million for rights to preclinical-stage ...

Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential for ...